GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...
GlaxoSmithKline Pharma is shifting focus to specialty treatments and preventive healthcare, emphasizing adult vaccines and ...
Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
Pharmaceutical giant GlaxoSmithKline (GSK) has agreed to pay up to $2.2 billion to settle most of lawsuits filed in U.S.
Shares of the UK-based pharma giant GlaxoSmithKline PLC ($GB:GSK) soared over 6% after the company announced a settlement of ...
London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...
In fact, the company shares have seen a cumulative rise of 5.39 per cent or GBP 78.50. On Thursday, the green streak ...
Topline results from the groundbreaking Salford Lung Study are encouraging for GSK's new respiratory drug - but the 'real world' story isn't quite so simple. GlaxoSmithKline (GSK) has announced ...
GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...